Evidence map›Paper›PMID 38346997›Full record

ArticleNature reviews. Disease primers2024

Author Correction: Hepatocellular carcinoma.

Josep M Llovet, Robin Kate Kelley, Augusto Villanueva, Amit G Singal, Eli Pikarsky, Sasan Roayaie, Riccardo Lencioni, Kazuhiko Koike, Jessica Zucman-Rossi, Richard S Finn

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature reviews. Disease primers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Josep M LlovetMount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. josep.llovet@mssm.edu.ORCID http://orcid.org/0000-0003-0547-2667
Robin Kate KelleyHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, CA, USA.
Augusto VillanuevaMount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-3585-3727
Amit G SingalDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Eli PikarskyThe Lautenberg Center for Immunology and Cancer Research, IMRIC, The Hebrew University of Jerusalem, Jerusalem, Israel.
Sasan RoayaieWhite Plains Hospital Center for Cancer Care, Montefiore Health, White Plains, NY, USA.
Riccardo LencioniDepartment of Radiology, Pisa University School of Medicine, Pisa, Italy.
Kazuhiko KoikeThe University of Tokyo, Department of Gastroenterology, Tokyo, Japan.
Jessica Zucman-RossiCentre de Recherche des Cordeliers, Sorbonne Université, Inserm, USPC, Université Paris Descartes, Université Paris Diderot, Paris, France.ORCID http://orcid.org/0000-0002-5687-0334
Richard S FinnDepartment of Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38346997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.